Kristen Nowak
Concepts (306)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polycystic Kidney, Autosomal Dominant | 20 | 2024 | 262 | 9.110 |
Why?
| | Renal Insufficiency, Chronic | 27 | 2025 | 617 | 5.670 |
Why?
| | Vascular Stiffness | 13 | 2025 | 494 | 3.560 |
Why?
| | Endothelium, Vascular | 17 | 2025 | 927 | 2.670 |
Why?
| | Blood Pressure | 14 | 2023 | 1786 | 2.040 |
Why?
| | Glomerular Filtration Rate | 12 | 2025 | 746 | 1.960 |
Why?
| | Kidney | 12 | 2025 | 1468 | 1.900 |
Why?
| | Kidney Failure, Chronic | 9 | 2020 | 570 | 1.850 |
Why?
| | Caloric Restriction | 3 | 2024 | 124 | 1.570 |
Why?
| | Sodium, Dietary | 3 | 2023 | 41 | 1.550 |
Why?
| | Vascular Diseases | 4 | 2021 | 243 | 1.390 |
Why?
| | Blood Vessels | 4 | 2024 | 187 | 1.390 |
Why?
| | Sodium | 3 | 2019 | 217 | 1.310 |
Why?
| | Hypertension | 7 | 2021 | 1295 | 1.280 |
Why?
| | Diet, Sodium-Restricted | 4 | 2020 | 36 | 1.220 |
Why?
| | Inflammation | 9 | 2025 | 2837 | 1.200 |
Why?
| | Disease Progression | 9 | 2024 | 2757 | 1.090 |
Why?
| | Brachial Artery | 10 | 2025 | 205 | 1.090 |
Why?
| | Cardiovascular Diseases | 13 | 2025 | 2111 | 1.040 |
Why?
| | Oxidative Stress | 13 | 2025 | 1317 | 1.020 |
Why?
| | Cognitive Dysfunction | 3 | 2025 | 383 | 0.950 |
Why?
| | Interleukin-1 | 3 | 2019 | 965 | 0.920 |
Why?
| | Cognition | 4 | 2025 | 1153 | 0.900 |
Why?
| | Renal Dialysis | 5 | 2019 | 435 | 0.900 |
Why?
| | Recombinant Fusion Proteins | 2 | 2017 | 665 | 0.870 |
Why?
| | Pulse Wave Analysis | 10 | 2025 | 272 | 0.870 |
Why?
| | Lipocalin-2 | 2 | 2024 | 79 | 0.870 |
Why?
| | Kidney Tubules | 1 | 2024 | 117 | 0.830 |
Why?
| | Intra-Abdominal Fat | 1 | 2024 | 91 | 0.830 |
Why?
| | Metformin | 2 | 2024 | 331 | 0.810 |
Why?
| | Aging | 8 | 2018 | 1864 | 0.790 |
Why?
| | Vasodilation | 8 | 2025 | 499 | 0.770 |
Why?
| | Fibroblast Growth Factors | 3 | 2019 | 172 | 0.740 |
Why?
| | Humans | 78 | 2025 | 137585 | 0.730 |
Why?
| | Middle Aged | 42 | 2025 | 33479 | 0.730 |
Why?
| | Curcumin | 1 | 2021 | 29 | 0.720 |
Why?
| | Endothelial Cells | 4 | 2023 | 785 | 0.720 |
Why?
| | Chronic Kidney Disease-Mineral and Bone Disorder | 2 | 2018 | 14 | 0.700 |
Why?
| | Male | 55 | 2025 | 67762 | 0.690 |
Why?
| | Double-Blind Method | 12 | 2025 | 1993 | 0.690 |
Why?
| | Aged | 33 | 2025 | 23961 | 0.680 |
Why?
| | Biomarkers | 9 | 2025 | 4149 | 0.670 |
Why?
| | Renal Agents | 1 | 2020 | 5 | 0.660 |
Why?
| | Systole | 1 | 2020 | 189 | 0.650 |
Why?
| | Dementia | 1 | 2023 | 259 | 0.620 |
Why?
| | Overweight | 2 | 2021 | 558 | 0.610 |
Why?
| | Female | 50 | 2025 | 73304 | 0.610 |
Why?
| | Polycystic Kidney Diseases | 1 | 2019 | 76 | 0.600 |
Why?
| | Spironolactone | 1 | 2019 | 36 | 0.600 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 54 | 0.590 |
Why?
| | Kidney Neoplasms | 1 | 2023 | 403 | 0.590 |
Why?
| | Potassium, Dietary | 1 | 2018 | 12 | 0.570 |
Why?
| | Drinking Water | 1 | 2019 | 84 | 0.560 |
Why?
| | Hyponatremia | 1 | 2018 | 42 | 0.560 |
Why?
| | Healthy Lifestyle | 1 | 2018 | 34 | 0.560 |
Why?
| | Primary Prevention | 2 | 2018 | 196 | 0.540 |
Why?
| | Interleukin-6 | 2 | 2020 | 778 | 0.540 |
Why?
| | Death | 1 | 2018 | 119 | 0.540 |
Why?
| | Autophagy | 1 | 2019 | 284 | 0.530 |
Why?
| | Obesity | 2 | 2021 | 2992 | 0.500 |
Why?
| | Cerebrovascular Circulation | 3 | 2025 | 243 | 0.500 |
Why?
| | Vitamin D | 5 | 2018 | 397 | 0.470 |
Why?
| | Energy Metabolism | 2 | 2024 | 922 | 0.460 |
Why?
| | Atherosclerosis | 2 | 2018 | 415 | 0.460 |
Why?
| | Adult | 26 | 2024 | 37929 | 0.450 |
Why?
| | Bacterial Infections | 1 | 2016 | 250 | 0.440 |
Why?
| | Sodium Bicarbonate | 3 | 2025 | 45 | 0.430 |
Why?
| | Longitudinal Studies | 5 | 2018 | 2844 | 0.400 |
Why?
| | Hypercapnia | 2 | 2023 | 53 | 0.400 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 2 | 2024 | 42 | 0.390 |
Why?
| | Sodium Chloride, Dietary | 2 | 2023 | 36 | 0.360 |
Why?
| | Acidosis | 2 | 2025 | 101 | 0.360 |
Why?
| | Apoptosis | 1 | 2019 | 2553 | 0.340 |
Why?
| | Carotid Arteries | 3 | 2018 | 206 | 0.340 |
Why?
| | Time Factors | 7 | 2021 | 6828 | 0.340 |
Why?
| | Regional Blood Flow | 7 | 2016 | 474 | 0.330 |
Why?
| | Young Adult | 12 | 2024 | 13209 | 0.320 |
Why?
| | Vascular Calcification | 2 | 2018 | 108 | 0.320 |
Why?
| | Cardiovascular System | 2 | 2023 | 137 | 0.310 |
Why?
| | Uric Acid | 2 | 2018 | 163 | 0.310 |
Why?
| | TRPP Cation Channels | 2 | 2020 | 85 | 0.300 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2023 | 445 | 0.300 |
Why?
| | Prospective Studies | 9 | 2023 | 7604 | 0.280 |
Why?
| | Risk Factors | 10 | 2025 | 10388 | 0.270 |
Why?
| | NF-kappa B | 4 | 2015 | 691 | 0.270 |
Why?
| | Cohort Studies | 5 | 2024 | 5742 | 0.270 |
Why?
| | Energy Intake | 2 | 2020 | 485 | 0.260 |
Why?
| | Independent Living | 2 | 2018 | 105 | 0.260 |
Why?
| | Femoral Artery | 2 | 2018 | 179 | 0.260 |
Why?
| | Hospitalization | 1 | 2016 | 2199 | 0.260 |
Why?
| | Phosphates | 2 | 2024 | 182 | 0.250 |
Why?
| | Organ Size | 2 | 2017 | 477 | 0.250 |
Why?
| | Brain | 1 | 2018 | 2668 | 0.240 |
Why?
| | Cross-Sectional Studies | 5 | 2024 | 5472 | 0.240 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2015 | 92 | 0.230 |
Why?
| | Kaplan-Meier Estimate | 2 | 2018 | 889 | 0.230 |
Why?
| | Chitinase-3-Like Protein 1 | 1 | 2024 | 19 | 0.220 |
Why?
| | Exercise | 4 | 2018 | 2057 | 0.220 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 201 | 0.220 |
Why?
| | Lanthanum | 1 | 2024 | 13 | 0.220 |
Why?
| | Antidiuretic Hormone Receptor Antagonists | 1 | 2024 | 9 | 0.220 |
Why?
| | Transcription Factor CHOP | 1 | 2014 | 31 | 0.220 |
Why?
| | Potassium | 1 | 2014 | 147 | 0.220 |
Why?
| | Inflammasomes | 1 | 2025 | 131 | 0.220 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2024 | 70 | 0.220 |
Why?
| | Chemokine CCL2 | 1 | 2024 | 115 | 0.210 |
Why?
| | Physical Fitness | 2 | 2013 | 209 | 0.210 |
Why?
| | Genotype | 2 | 2020 | 1916 | 0.210 |
Why?
| | Minerals | 2 | 2019 | 42 | 0.210 |
Why?
| | Magnetic Resonance Imaging | 3 | 2024 | 3566 | 0.210 |
Why?
| | Obesity, Abdominal | 1 | 2024 | 48 | 0.210 |
Why?
| | Blood Flow Velocity | 2 | 2023 | 413 | 0.210 |
Why?
| | Bufanolides | 1 | 2013 | 4 | 0.210 |
Why?
| | Pilot Projects | 6 | 2025 | 1710 | 0.210 |
Why?
| | Diet, Ketogenic | 1 | 2023 | 37 | 0.210 |
Why?
| | Glycosphingolipids | 1 | 2023 | 7 | 0.200 |
Why?
| | Pneumonia, Bacterial | 1 | 2014 | 116 | 0.200 |
Why?
| | Cystatin C | 1 | 2013 | 65 | 0.200 |
Why?
| | Body Mass Index | 2 | 2024 | 2389 | 0.190 |
Why?
| | Inflammation Mediators | 3 | 2025 | 513 | 0.190 |
Why?
| | Reactive Oxygen Species | 2 | 2023 | 622 | 0.190 |
Why?
| | Calcinosis | 1 | 2014 | 235 | 0.190 |
Why?
| | Blood Glucose | 2 | 2021 | 2186 | 0.190 |
Why?
| | Community-Acquired Infections | 1 | 2014 | 174 | 0.190 |
Why?
| | Informed Consent | 1 | 2023 | 175 | 0.190 |
Why?
| | Endoplasmic Reticulum | 1 | 2014 | 265 | 0.190 |
Why?
| | Adolescent | 7 | 2021 | 21513 | 0.180 |
Why?
| | Patients | 1 | 2023 | 175 | 0.180 |
Why?
| | Forearm | 2 | 2009 | 119 | 0.180 |
Why?
| | Kidney Diseases | 1 | 2025 | 408 | 0.180 |
Why?
| | Treatment Outcome | 6 | 2020 | 10811 | 0.180 |
Why?
| | Creatinine | 1 | 2013 | 499 | 0.180 |
Why?
| | Case-Control Studies | 4 | 2025 | 3556 | 0.170 |
Why?
| | Sex Factors | 3 | 2025 | 2071 | 0.170 |
Why?
| | Endothelin-1 | 2 | 2009 | 182 | 0.170 |
Why?
| | Parathyroid Hormone | 2 | 2018 | 108 | 0.170 |
Why?
| | Euthyroid Sick Syndromes | 1 | 2020 | 1 | 0.170 |
Why?
| | Follow-Up Studies | 3 | 2019 | 5131 | 0.170 |
Why?
| | Allopurinol | 2 | 2018 | 63 | 0.170 |
Why?
| | Salicylates | 2 | 2015 | 28 | 0.170 |
Why?
| | Cytokines | 2 | 2018 | 2085 | 0.160 |
Why?
| | Nutritive Value | 1 | 2020 | 37 | 0.160 |
Why?
| | C-Reactive Protein | 2 | 2018 | 410 | 0.160 |
Why?
| | Caspase Inhibitors | 1 | 2019 | 81 | 0.160 |
Why?
| | Child | 5 | 2023 | 21935 | 0.160 |
Why?
| | Retrospective Studies | 4 | 2024 | 15657 | 0.160 |
Why?
| | Weight Loss | 1 | 2015 | 787 | 0.160 |
Why?
| | Salinity | 1 | 2019 | 20 | 0.160 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2021 | 1477 | 0.150 |
Why?
| | Bangladesh | 1 | 2019 | 56 | 0.150 |
Why?
| | Drinking | 1 | 2019 | 42 | 0.150 |
Why?
| | Adiposity | 1 | 2024 | 518 | 0.150 |
Why?
| | Lipoproteins, HDL | 1 | 2019 | 77 | 0.150 |
Why?
| | Patient Advocacy | 1 | 2019 | 76 | 0.150 |
Why?
| | Caspases | 1 | 2019 | 247 | 0.150 |
Why?
| | Vitamin D Deficiency | 1 | 2010 | 186 | 0.150 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2009 | 204 | 0.150 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2008 | 48 | 0.140 |
Why?
| | I-kappa B Proteins | 1 | 2008 | 81 | 0.140 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2018 | 90 | 0.140 |
Why?
| | Animals | 6 | 2023 | 36940 | 0.140 |
Why?
| | Cross-Over Studies | 4 | 2018 | 564 | 0.140 |
Why?
| | Sepsis | 1 | 2014 | 617 | 0.140 |
Why?
| | Fathers | 1 | 2018 | 50 | 0.140 |
Why?
| | Enteral Nutrition | 1 | 2020 | 202 | 0.140 |
Why?
| | Free Radical Scavengers | 1 | 2007 | 88 | 0.140 |
Why?
| | Healthy Aging | 1 | 2018 | 35 | 0.140 |
Why?
| | Diet | 1 | 2025 | 1278 | 0.140 |
Why?
| | Dietary Supplements | 2 | 2017 | 561 | 0.140 |
Why?
| | Pain | 1 | 2023 | 756 | 0.140 |
Why?
| | Calcitriol | 1 | 2017 | 58 | 0.130 |
Why?
| | Cholecalciferol | 1 | 2017 | 60 | 0.130 |
Why?
| | Health Status | 1 | 2012 | 792 | 0.130 |
Why?
| | Critical Illness | 2 | 2020 | 811 | 0.130 |
Why?
| | Enzyme Inhibitors | 2 | 2016 | 840 | 0.130 |
Why?
| | Hyperuricemia | 1 | 2016 | 44 | 0.130 |
Why?
| | Immunity, Humoral | 1 | 2017 | 116 | 0.130 |
Why?
| | Vasoconstriction | 1 | 2007 | 202 | 0.130 |
Why?
| | Up-Regulation | 1 | 2019 | 843 | 0.130 |
Why?
| | Ascorbic Acid | 1 | 2007 | 177 | 0.120 |
Why?
| | Chronic Disease | 2 | 2019 | 1793 | 0.120 |
Why?
| | Leg | 1 | 2007 | 236 | 0.120 |
Why?
| | Intensive Care Units | 1 | 2021 | 827 | 0.120 |
Why?
| | Severity of Illness Index | 3 | 2018 | 2828 | 0.120 |
Why?
| | Neuroimaging | 1 | 2018 | 259 | 0.120 |
Why?
| | Program Development | 1 | 2018 | 364 | 0.120 |
Why?
| | Immunity, Cellular | 1 | 2017 | 268 | 0.120 |
Why?
| | Signal Transduction | 2 | 2019 | 5079 | 0.120 |
Why?
| | Cell Nucleus | 1 | 2008 | 620 | 0.120 |
Why?
| | Communicable Diseases | 1 | 2017 | 159 | 0.120 |
Why?
| | Nutritional Status | 1 | 2018 | 350 | 0.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 804 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2012 | 2057 | 0.120 |
Why?
| | Hypoglycemic Agents | 1 | 2024 | 1291 | 0.120 |
Why?
| | Family | 1 | 2019 | 671 | 0.110 |
Why?
| | Risk Assessment | 3 | 2021 | 3457 | 0.110 |
Why?
| | Age of Onset | 1 | 2016 | 518 | 0.110 |
Why?
| | Peripheral Arterial Disease | 1 | 2021 | 475 | 0.110 |
Why?
| | Prenatal Diagnosis | 1 | 2016 | 201 | 0.110 |
Why?
| | Myocardial Infarction | 1 | 2022 | 1046 | 0.110 |
Why?
| | Patient Care Team | 1 | 2019 | 631 | 0.110 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1430 | 0.100 |
Why?
| | Acute Kidney Injury | 1 | 2021 | 815 | 0.100 |
Why?
| | Aged, 80 and over | 3 | 2025 | 7635 | 0.100 |
Why?
| | Communication | 1 | 2019 | 879 | 0.100 |
Why?
| | Program Evaluation | 1 | 2018 | 898 | 0.100 |
Why?
| | Neuropsychological Tests | 1 | 2018 | 1023 | 0.100 |
Why?
| | Survival Rate | 1 | 2018 | 1972 | 0.100 |
Why?
| | Prognosis | 2 | 2021 | 4030 | 0.100 |
Why?
| | Age Factors | 4 | 2025 | 3295 | 0.100 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2015 | 350 | 0.100 |
Why?
| | NADPH Oxidases | 2 | 2013 | 113 | 0.100 |
Why?
| | Drug Therapy, Combination | 2 | 2015 | 1066 | 0.090 |
Why?
| | Mothers | 1 | 2018 | 754 | 0.090 |
Why?
| | Fasting | 2 | 2023 | 281 | 0.090 |
Why?
| | United States | 2 | 2019 | 14841 | 0.090 |
Why?
| | Prevalence | 1 | 2018 | 2734 | 0.090 |
Why?
| | Physicians | 1 | 2019 | 910 | 0.090 |
Why?
| | Quality of Life | 1 | 2012 | 2892 | 0.080 |
Why?
| | Lipoproteins, LDL | 2 | 2012 | 116 | 0.080 |
Why?
| | Mutation | 1 | 2020 | 3958 | 0.080 |
Why?
| | Vascular Resistance | 2 | 2012 | 375 | 0.080 |
Why?
| | Aorta | 2 | 2015 | 417 | 0.070 |
Why?
| | Vasodilator Agents | 2 | 2009 | 331 | 0.070 |
Why?
| | Ultrasonography, Doppler, Transcranial | 1 | 2025 | 45 | 0.060 |
Why?
| | Middle Cerebral Artery | 1 | 2025 | 53 | 0.060 |
Why?
| | Infant, Newborn | 1 | 2016 | 6079 | 0.060 |
Why?
| | Ketocholesterols | 1 | 2014 | 7 | 0.060 |
Why?
| | Nitric Oxide | 2 | 2011 | 915 | 0.060 |
Why?
| | Ezetimibe | 1 | 2014 | 24 | 0.060 |
Why?
| | Vegetables | 1 | 2025 | 157 | 0.060 |
Why?
| | Dilatation, Pathologic | 1 | 2014 | 62 | 0.060 |
Why?
| | Azetidines | 1 | 2014 | 43 | 0.050 |
Why?
| | Simvastatin | 1 | 2014 | 61 | 0.050 |
Why?
| | Apolipoproteins E | 1 | 2014 | 83 | 0.050 |
Why?
| | Pravastatin | 1 | 2023 | 41 | 0.050 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2014 | 107 | 0.050 |
Why?
| | Bicarbonates | 1 | 2023 | 44 | 0.050 |
Why?
| | Postmenopause | 1 | 2025 | 366 | 0.050 |
Why?
| | Cysts | 1 | 2024 | 113 | 0.050 |
Why?
| | Biological Availability | 1 | 2012 | 148 | 0.050 |
Why?
| | Compliance | 1 | 2012 | 49 | 0.050 |
Why?
| | Infant | 1 | 2016 | 9465 | 0.050 |
Why?
| | Microcirculation | 1 | 2012 | 149 | 0.050 |
Why?
| | Australia | 1 | 2023 | 315 | 0.050 |
Why?
| | Nutrition Surveys | 1 | 2023 | 266 | 0.050 |
Why?
| | Global Health | 1 | 2025 | 386 | 0.050 |
Why?
| | Odds Ratio | 1 | 2014 | 1070 | 0.040 |
Why?
| | Meta-Analysis as Topic | 1 | 2012 | 186 | 0.040 |
Why?
| | Gonadal Steroid Hormones | 1 | 2022 | 140 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2022 | 329 | 0.040 |
Why?
| | Nitroglycerin | 1 | 2010 | 17 | 0.040 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2010 | 17 | 0.040 |
Why?
| | Receptors, Calcitriol | 1 | 2010 | 55 | 0.040 |
Why?
| | Muscles | 1 | 2021 | 326 | 0.040 |
Why?
| | Colorado | 2 | 2017 | 4565 | 0.040 |
Why?
| | Triiodothyronine, Reverse | 1 | 2020 | 2 | 0.040 |
Why?
| | Cholesterol, LDL | 1 | 2012 | 365 | 0.040 |
Why?
| | Triiodothyronine | 1 | 2020 | 43 | 0.040 |
Why?
| | Prediabetic State | 1 | 2013 | 253 | 0.040 |
Why?
| | Thyroxine | 1 | 2020 | 62 | 0.040 |
Why?
| | Chicago | 1 | 2019 | 61 | 0.040 |
Why?
| | Lymphocytes | 1 | 2022 | 397 | 0.040 |
Why?
| | Lipids | 1 | 2014 | 672 | 0.040 |
Why?
| | Thyrotropin | 1 | 2020 | 114 | 0.040 |
Why?
| | Superoxide Dismutase | 1 | 2012 | 346 | 0.040 |
Why?
| | Diet Records | 1 | 2009 | 83 | 0.040 |
Why?
| | Receptor, Endothelin A | 1 | 2009 | 65 | 0.040 |
Why?
| | Monocytes | 1 | 2022 | 563 | 0.040 |
Why?
| | Logistic Models | 1 | 2014 | 2074 | 0.040 |
Why?
| | Sulfaphenazole | 1 | 2008 | 3 | 0.040 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2008 | 54 | 0.040 |
Why?
| | Cytochrome P-450 CYP2C9 | 1 | 2008 | 20 | 0.040 |
Why?
| | omega-N-Methylarginine | 1 | 2008 | 27 | 0.040 |
Why?
| | Testosterone | 1 | 2022 | 409 | 0.040 |
Why?
| | Nitroprusside | 1 | 2008 | 69 | 0.040 |
Why?
| | Professional-Family Relations | 1 | 2019 | 143 | 0.040 |
Why?
| | Sex Characteristics | 1 | 2023 | 762 | 0.040 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2019 | 151 | 0.040 |
Why?
| | Ultrasonography, Doppler, Duplex | 1 | 2007 | 43 | 0.030 |
Why?
| | Acetylcholine | 1 | 2008 | 185 | 0.030 |
Why?
| | Nitric Oxide Synthase | 1 | 2008 | 240 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2021 | 956 | 0.030 |
Why?
| | Calcium | 1 | 2013 | 1199 | 0.030 |
Why?
| | Regression Analysis | 1 | 2020 | 1024 | 0.030 |
Why?
| | Arteries | 1 | 2009 | 269 | 0.030 |
Why?
| | Databases, Factual | 1 | 2013 | 1357 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2014 | 3015 | 0.030 |
Why?
| | Epinephrine | 1 | 2007 | 139 | 0.030 |
Why?
| | Cholesterol | 1 | 2019 | 410 | 0.030 |
Why?
| | Vasoconstrictor Agents | 1 | 2007 | 139 | 0.030 |
Why?
| | Norepinephrine | 1 | 2007 | 204 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2007 | 413 | 0.030 |
Why?
| | Reference Values | 1 | 2007 | 816 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2020 | 645 | 0.030 |
Why?
| | Phosphorylation | 1 | 2009 | 1759 | 0.030 |
Why?
| | Incidence | 1 | 2021 | 2804 | 0.030 |
Why?
| | Acute Disease | 1 | 2017 | 1007 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2031 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2014 | 5757 | 0.030 |
Why?
| | Recovery of Function | 1 | 2017 | 653 | 0.030 |
Why?
| | Decision Making | 1 | 2019 | 900 | 0.020 |
Why?
| | Insulin | 1 | 2013 | 2409 | 0.020 |
Why?
| | Heart Rate | 1 | 2015 | 822 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2023 | 5778 | 0.020 |
Why?
| | Mice | 1 | 2009 | 17787 | 0.010 |
Why?
|
|
Nowak's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|